{"id":"mek","name":"MEK1/2","symbol":"MAP2K1, MAP2K2","route":"/targets/mek/","asOf":"2026-09-10","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6840","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169032","uniprot":"https://www.uniprot.org/uniprotkb/Q02750/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q02750","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3587","open-targets":"https://platform.opentargets.org/target/ENSG00000169032","civic":"https://civicdb.org/genes/5604/summary","oncokb":"https://www.oncokb.org/gene/MAP2K1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP2K1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MAP2K1","depmap":"https://depmap.org/portal/gene/MAP2K1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000169032-MAP2K1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5604","omim":"https://www.omim.org/entry/176872"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6842","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126934","uniprot":"https://www.uniprot.org/uniprotkb/P36507/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P36507","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2964","open-targets":"https://platform.opentargets.org/target/ENSG00000126934","civic":"https://civicdb.org/genes/5605/summary","oncokb":"https://www.oncokb.org/gene/MAP2K2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP2K2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MAP2K2","depmap":"https://depmap.org/portal/gene/MAP2K2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000126934-MAP2K2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5605","omim":"https://www.omim.org/entry/601263"}],"products":[{"id":"atebimetinib","name":"Atebimetinib","status":"phase-3","modality":"small molecule","route":"/drugs/atebimetinib/"},{"id":"gc101-til","name":"GC101 TIL","status":"phase-2","modality":"TIL therapy","route":"/drugs/gc101-til/"},{"id":"mirdametinib","name":"Mirdametinib","status":"approved","modality":"Small-molecule allosteric MEK1/2 inhibitor","route":"/drugs/mirdametinib/"},{"id":"selumetinib","name":"Selumetinib","status":"approved","modality":"Small-molecule allosteric MEK1/2 inhibitor","route":"/drugs/selumetinib/"},{"id":"trametinib","name":"Trametinib","status":"approved","modality":"Small-molecule allosteric MEK1/2 inhibitor","route":"/drugs/trametinib/"},{"id":"tunlametinib","name":"Tunlametinib","status":"approved","modality":"Oral MEK1/2 inhibitor","route":"/drugs/tunlametinib/"}],"trials":[{"id":"nct04940052","name":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto","nct":"NCT04940052","phase":"3","status":"active"},{"id":"beacon-crc","name":"BEACON CRC","nct":"NCT02928224","phase":"3","status":"positive"},{"id":"imblaze370","name":"IMblaze370","nct":"NCT02788279","phase":"3","status":"negative"},{"id":"nct01933932","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","nct":"NCT01933932","phase":"3","status":"active"},{"id":"cobrim","name":"coBRIM","nct":"NCT01689519","phase":"3","status":"positive"},{"id":"combi-d","name":"COMBI-d","nct":"NCT01584648","phase":"3","status":"positive"},{"id":"nct07562152","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","nct":"NCT07562152","phase":"3","status":"recruiting"},{"id":"nct06008106","name":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","nct":"NCT06008106","phase":"3","status":"recruiting"},{"id":"nct06008119","name":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","nct":"NCT06008119","phase":"3","status":"recruiting"},{"id":"nct03784014","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","nct":"NCT03784014","phase":"3","status":"completed"},{"id":"nct07440290","name":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi","nct":"NCT07440290","phase":"2/3","status":"recruiting"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"national-lung-matrix-trial","name":"National Lung Matrix Trial","nct":"NCT02664935","phase":"2","status":"completed"},{"id":"roar","name":"ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort","nct":"NCT02034110","phase":"2","status":"positive"},{"id":"checkmate-142","name":"CheckMate 142","nct":"NCT02060188","phase":"2","status":"positive"},{"id":"brf113928","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","nct":"NCT01336634","phase":"2","status":"positive"},{"id":"nct07560111","name":"A Phase II Study of GC101 in NSCLC","nct":"NCT07560111","phase":"2","status":"recruiting"},{"id":"nct02151084","name":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer","nct":"NCT02151084","phase":"2","status":"active"},{"id":"nct06703398","name":"A Study of GC101 TIL in Advanced Melanoma","nct":"NCT06703398","phase":"2","status":"recruiting"},{"id":"nct06153173","name":"Mirdametinib in Histiocytic Disorders","nct":"NCT06153173","phase":"2","status":"recruiting"},{"id":"nct07237100","name":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma","nct":"NCT07237100","phase":"2","status":"recruiting"},{"id":"nct03899155","name":"Pan Tumor Rollover Study","nct":"NCT03899155","phase":"2","status":"recruiting"},{"id":"nct04417621","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","nct":"NCT04417621","phase":"2","status":"active"},{"id":"nct07061951","name":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","nct":"NCT07061951","phase":"2","status":"recruiting"},{"id":"nct05372354","name":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ","nct":"NCT05372354","phase":"1/2","status":"recruiting"},{"id":"nct05874414","name":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","nct":"NCT05874414","phase":"1/2","status":"recruiting"},{"id":"nct05358249","name":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","nct":"NCT05358249","phase":"1/2","status":"active"},{"id":"nct07468071","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","nct":"NCT07468071","phase":"1/2","status":"recruiting"},{"id":"nct07619521","name":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","nct":"NCT07619521","phase":"1/2","status":"recruiting"},{"id":"nct06456138","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","nct":"NCT06456138","phase":"1/2","status":"planned"},{"id":"nct05275374","name":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","nct":"NCT05275374","phase":"1/2","status":"planned"}],"pathways":["aml-signalling","bladder-cancer-signalling","breast-cancer-signalling","cml-signalling","melanoma-signalling","nsclc-signalling","thyroid-cancer-signalling"],"companies":["astrazeneca","immuneering","merck","novartis","pierre-fabre","shanghai-juncell-therapeutics","shanghai-kechow-pharma","springworks"],"keyPapers":["paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}